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Objectives:To evaluate the immunogenicity and safety of an Escherichia Coli 
produced bivalent human papillomavirus (type 16 and 18) vaccine administered in 
girls aged 9-17 years. 
Method: Participants were enrolled afer signing the informed consent and met the 
inclusion criterias but not the exclusion ones.This is an open label designed 
immunogenicity and safety study.Subjects of 9-14 years old were randomly assinged 
to the standard 0/1/6 month schedule or the alternative 0/6 month schedule,while all 
subjects of 15-26 years old the standard one.Participants would receive one dose 
vaccine each visit during specific time window.After injection all reactions occured in 
1 month after injecion were required to be recorded on the dinary card.Blood samples 
were collected at 0,6,7 month to evaluate the immune response to detect the IgG 
antibody and the nuetrolizing antibody of vaccine related HPV type. 
Results: 1031 subjects from Yancheng city in Jiangsu province were recurited 
during the october of 2015.979 participants were entrolled and 934 got the qualified 
blood sample detected.In per-protocol and intention-to treat dataset the immune 
response of the 9-14 years of 3 dose was demostrated to be noninferior to the 18-26 
years of 3 dose with the HPV16,18 geometric mean concentration ratio being 
1.70,1.89 above.The same conclusion could be draw from the 9-14 years of 2 dose 
compared with the 18-26 years with the ratio being 1.32,1.21 above. 
The administration of the Escherichia Coli produced HPV 16/18 vaccine was 
tolerated in preadolesenct girls.The rate of total adverse events was similar in 
participants of 9-14 years of 2 dose,9-14 years of 3 dose,9-17 years of 3 dose,28-26 
years of 3 dose with the rate around 67%-80%.The systemic adverse event occuring in 
the four groups were around 54%-63%.The most six common systemic adverse events 
were pain at injection site,fever,cough,fatigue,swelling at injection site.The 
















being grade 1 and 55.47% related to vaccination.Seriou adverse event was rare,and 
the rate was 0.31%. 
Conclusions: 
1) Immunogenicity induced by the Escherichia Coli produced humanpapillomavirus 
vaccine in girls aged 9-17 years is non-inferior as compared to 18-26 women 
when administered accroding to the standard 0/1/6 monthe schedule. 
2) Immunogenicity induced by the candidate vaccine in girls of 9-14 years receiving 
2 doses with six months interval is non-inferior as compared to 18-26 women 
receiving 3 doses. 
3) The candidate vaccine was tolerated in girls aged 9-17 years. 
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缩略语 英文名称 中文名称 
AE Adverse event 不良事件 
CCTS China Clinical Trial Statistics Working Group 中国临床试验生物统计学组 
CI Confidence Interval 置信区间 
CIN Cervical intraepithelial neoplasia 宫颈上皮内瘤变 
CRF Case Report Form 病例报告表 
DMEM Dulbecco's Modified Eagle Medium 良伊格尔培养基 
DNA Deoxyribonucleic acid 脱氧核糖核酸 
eCRF Electronic Case Report Form 电子病例报告表 
ED50 50% Effective Dose 半数有效量 
EDC Electronic Data Capture System 电子数据采集系统 
EU ELISA unit ELISA 单位 
FAS Full Analysis Set  全分析集 
GCP Good Clinical Practice 临床试验规范标准 
GMC Geometric Mean Concentration 几何平均浓度 
HPV Human Papillomavirus 人乳头瘤病毒 
ICH International Conference on Harmonization 国际协调会议 
ID Identification 身份 
IEC Independent Ethics Committee 独立伦理委员会 
IgG Immunoglobulin G 免疫球蛋白 G 
ITT Intention to treat 意向性治疗数据集 
ITT-I Intention to treat (Immunogenicity) 免疫原性的意向性治疗数据集 
mITT Modified intention to treat 改良的意向性治疗数据集 
mITT-I Modified intention to treat (Immunogenicity) 改良的免疫原性意向性治疗数据集 
OD Optical Density 光密度 
PBST Phosphate Buffered Saline with Tween 磷酸盐吐温缓冲液 
















PPS-I Per-protocol Set (Immunogenicity) 免疫原性研究的符合方案数据集 
PT Preferred Term 首选术语 
PV Papillomavirus 动物乳头状病毒 
QA Quality Assurance 质量保证人员 
QNS Quantity not sufficient 量不足 
SAE Serious adverse event 严重不良事件 
SAP Statistic analysis plan 统计分析计划 
SD Standard deviation 标准偏差 
SOC System Organ Classification 系统器官分类 
SOP Standard Operating Procedure 标准操作规程 
SS Safety Set 安全性数据集 
VLP Virus-like particle 病毒样颗粒 
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